BIO in tu­mult as CEO abrupt­ly ex­its; Some good PhI­II news; Da­ta is­sues still plague No­var­tis' gene ther­a­py; Hot tar­gets for M&A?; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Many thanks to all those who turned up at the EU­BIO event in Lon­don this week — the whole team is now bask­ing in the pos­i­tive feed­back we got and the pho­tos are giv­ing me FO­MO. End­points is look­ing to bring these in-per­son gath­er­ings to many more cor­ners of the world. Stay tuned.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER